

PROVIDER Update



CONTRACTUAL | MARCH 13, 2026 | UPDATE 26-333 | 8 PAGES

1st Quarter 2026 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after May 15, 2026

The Health Net* Pharmacy Advisory Committee approved updates to the Injectable Medication HCPCS/Division of Financial Responsibility (DOFR) Crosswalk on February 2, 2026. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, **effective May 15, 2026**, are listed on pages 2-8 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- **11 new injectable** medications to be added to the crosswalk
- **98 updates and changes** to current injectable medication procedure codes
- **8 new biosimilars** and updates to be added to the crosswalk
- **13 new generic** drugs

Need help? Contact us

Relevant sections of Health Net's provider operations manuals will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library under Quick Links*, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Health Net Employer Group

HMO, POS & PPO – 800-641-7761

Medi-Cal (including CS and ECM providers)
– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

New injectable medications to be added to the Injectable Medication HCPCS/DOFR Crosswalk

The following medications have been approved as additions to the crosswalk reference table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9321	Epkinly®	Injection, epcoritamab-bysp, 0.16 mg	Therapeutic injection	Chemotherapy ¹
J3590	Exdensur®	Depemokimab-ulaa injection, for subcutaneous use	Therapeutic injection	
J2790	HyperRHO®	Injection, Rho (D) immune globulin, human, full dose, 300 mcg (1500 international unit (IU))	Therapeutic injection	
J2788	HyperRHO® Mini-Dose	Injection, Rho (D) immune globulin, human, mini-dose, 50 mcg (250 IU)	Therapeutic injection	
J3590	Itvisma®	Onasemnogene abeparvovec-brve intrathecal injection 1.2 x 10 ¹⁴ vector genomes (vg)/3 mL	Therapeutic injection	
J3590	Nemlivio®	Nemolizumab-ilto injection, for subcutaneous use	Self-injectable	
J3490	Redemplo®	Plozasiran sodium subcutaneous solution in a pre-filled syringe 25 mg/ 0.5 mL (base equivalent)	Self-injectable	
J3590	Voyxact®	Sibeprenlimab-szsi subcutaneous solution pre-filled syringe 400 mg/2 mL	Self-injectable	
J3590	Waskyra™	Etuvetidigene autotemcel	Therapeutic injection	
J3590	Yartemlea®	Narsoplimab-wuug injection, for intravenous use	Therapeutic injection	
J3490	Zycubo®	Copper histidinate for injection, for subcutaneous use	Self-injectable	Chemotherapy ¹

Updates/changes to current injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk reference table.

HCPCS	Drug name	Generic name	Comment
J0795	Acthrel®	Corticotropin ovine triflutate	Discontinued
J2504	Adagen®	Pegademase bovine, 25 IU	Discontinued
J3490	Adlyxin®	Lixisenatide solution	Discontinued
J0190	Akineton®	Biperiden lactate, per 5 mg	Discontinued
J0216	Alfentanil	Injection, alfentanil hydrochloride (HCl), 500 mcg	Discontinued
J9215	Alferon N®	Interferon alfa-N3 (human leukocyte derived), 250,000 IU injection	Discontinued

Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
J0215	Amevive®	Alefacept	Discontinued
J0288	Amphotec®	Ampho B cholesteryl sulfate	Discontinued
J1451	Antizol®	Fomepizole, 15 mg	Brand discontinued; generic alternatives are still active
J0380	Aramine®	Metaraminol bitartrate	Discontinued
Q2037	Avtozma®	Tocilizumab-anoh, intravenous injection (IV), biosimilar to Actemra®	Replaces Q0237
J0470	Bal in oil	Dimecaprol injection	Discontinued
Q0222	Bebtelovimab	Bebtelovimab intravenous solution 175 mg/2 mL	Discontinued
J9037	Blenrep®	Belantamab mafodotin-blmf for intravenous solution, 100 mg	Discontinued
J3490	Bydureon®	Exenatide extended release injection	Discontinued
J3490	Bydureon BCise®	Exenatide extended release injectable suspension 2 mg	Discontinued
J3490	Byetta®	Exenatide injection	Discontinued
J0637	Cancidas®	Caspofungin acetate	Brand discontinued; code is still active
J0670	Carbocaine®	Mepivacaine hydrochloride 10 mL	Brand discontinued; generic alternatives are still active
J1566	Carimune® NF	Immune globulin, intravenous, lyophilized (e.g., powder), 500 mg	Brand discontinued; alternatives are still active
J0710	Cefadyl®	Cephapirin sodium	Discontinued
J0715	Cefizox®	Ceftizoxime sodium/500 mg	Discontinued
J0715	Cefizox® in dextrose 5% in water (D5W)	Ceftizoxime sodium/500 mg	Discontinued
J0525	Cefotetan®	Cefotetan disodium, 10 mg	Brand discontinued; generic alternatives are still active
J0713	Ceptaz®	Ceftazidime per 500 mg	Brand discontinued; generic alternatives are still active
J0205	Ceredase®	Alglucerase injection	Discontinued
J0698	Claforan®	Cefotaxime sodium injection	Brand discontinued; generic alternatives are still active
J0698	Claforan® in D5W	Cefotaxime sodium injection	Brand discontinued; generic alternatives are still active
J9027	Clolar®	Clofarabine injection	Brand discontinued; generic alternatives are still active
J2402	Clorotekal®	Chloroprocaine hydrochloride injection, for intrathecal use	Discontinued
J9120	Cosmegen®	Dactinomycin, 0.5 mg	Brand discontinued; generic alternatives are still active

Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
J2650	Cotolone®	Prednisolone acetate injection	Discontinued
J0878	Cubicin®	Daptomycin injection	Brand discontinued; generic alternatives are still active
J9151	DaunoXome®	Daunorubicin citrate liposomal formulation, 10 mg	Discontinued
90714	Decavac™	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals ages 7 years or older, for intramuscular use	Brand discontinued; tenivac still active
J1094	Dekasol long-acting	Dexamethasone acetate	Discontinued
J9098	DepoCyt®	Cytarabine liposome, 10 mg	Discontinued
J1750	Dexferrum®	Iron dextran, 50 mg	Discontinued
J7100	Dextran 40 in D5W	Dextran 40 infusion	Brand discontinued; generic alternatives are still active
J7100	Dextran 40 in sodium chloride (NaCl)	Dextran 40 infusion	Brand discontinued; generic alternatives are still active
J7110	Dextran 75 in D5W	Dextran 75 infusion	Brand discontinued; generic alternatives are still active
J7110	Dextran 75 in NaCl	Dextran 75 infusion	Brand discontinued; generic alternatives are still active
J1162	Digibind®	Digoxin immune fragment antigen-binding (ovine)	Brand discontinued; DigiFab® is active brand
J1267	Doribax™	Doripenem, 10 mg	Discontinued
J9130	DTIC-Dome®	Dacarbazine, 100 mg injection	Brand discontinued; generic alternatives are still active
J1130	Dyloject™	Diclofenac sodium, 0.5 mg, Injection	Discontinued
J9263	Eloxatin®	Oxaliplatin	Brand discontinued; generic alternatives are still active
J9020	Elspar®	Asparaginase injection, 10,000 units	Discontinued
J0350	Eminase®	Anistreplase 30 units	Discontinued
J9326	Emrelis™	Telisotuzumab vedotin-tllv for injection, for intravenous use	Replaces J9999
J3403	Encelto™	Revakinagene taroretcel-lwey intravitreal implant 200,000 cells	Replaces J3590
J1330	Ergonovine maleate	Ergonovine maleate injection	Discontinued
J9019	Erwinaze	Asparaginase erwinia chrysanthemi injection	Discontinued
J0713	Fortaz®	Ceftazidime per 500 mg	Brand discontinued; generic alternatives are still active

Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
J0713	Fortaz® in d5w	Ceftazidime per 500 mg	Brand discontinued; generic alternatives are still active
J1457	Ganite®	Gallium nitrate injection	Discontinued
90649	Gardasil®	Human papilloma virus (HPV) vaccine, types 6, 11, 16, and 18 (quadrivalent), 3 dose schedule, for intramuscular use	Discontinued
J0395	Genesa	Arbutamine HCl injection	Discontinued
J7100	Gentran 40 in D5W	Dextran 40 infusion	Brand discontinued; generic alternatives are still active
J1710	Hydrocortone®	Hydrocortisone sodium phosphate injection	Discontinued
J1729	Hydroxyprogesterone caproate	Hydroxyprogesterone caproate, 1.25 gm/5 mL solution	Discontinued
J9256	Imaavy™	Nipocalimab-aahu IV solution	Replaces J3590
Q5109	Ixifi™	Infliximab-qbtx, biosimilar, 10 mg	Discontinued
Q5160	Jobevne™	Bevacizumab-nwgd, biosimilar to Avastin®	Replaces J3590
C9307	Lynozofic™	Injection, livoseltamab-gcpt, 1 mg	Replaces J9999
J0694	Mefoxin® in dextrose	Cefoxitin sodium injection	Brand discontinued; generic alternatives are still active
J9270	Mithracin®	Plicamycin, 2.5 mg	Discontinued
90704	Mumpsvax®	Mumps vaccine, for subcutaneous use	Discontinued
J3305	Neutrexin®	Trimetrexate glucuronate	Discontinued
J1837	Noxafil®	Posaconazole Injection	Replaces J3490
J7505	Orthoclone OKT3®	Monoclonal antibodies	Discontinued
J2513	Pentastarch 10%	Pentastarch 10% solution	Discontinued
J2650	Predacort 50	Prednisolone acetate injection	Discontinued
J2650	Pred-ject-50	Prednisolone acetate injection	Discontinued
J2260	Primacor®	Milrinone lactate/5 mg	Discontinued
J2260	Primacor® in 5% dextrose	Milrinone lactate/5 mg	Discontinued
J2670	Priscoline®	Totazoline hydrochloride injection	Discontinued
J7174	Qfitlia™	Fitusiran injection, for subcutaneous use	Replaces J3490
J1945	Refludan®	Lepirudin	Discontinued
J7100	Rheomacrodex® in NaCl	Dextran 40 infusion	Brand discontinued; generic alternatives are still active
J3402	Ryoncil®	Remestemcel-L-rknd 2 x 3.8 mL suspension for IV infusion kit	Replaces J3590

Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
J3387	Skysona™	Elivaldogene autotemcel IV suspension	Relaces J3590
J2910	Solganal	Aurothiogluucose injection	Discontinued
J9165	Stilphostrol	Diethylstilbestrol injection, 250 mg	Discontinued
J2995	Streptase®	Streptokinase/250000 IU	Discontinued
J3490	Symlin®	Pramlintide acetate injection	Discontinued
J1073	Testopel®	Testosterone pellet, 75 mg	Replaces S0189
90585	Tice® Bacillus Calmette-Guérin 50 mg	Bacillus Calmette-Guerin vaccine for tuberculosis, live, for percutaneous use	Discontinued
J3280	Torecan®	Thiethylperazine maleate injection	Discontinued
J1190	Totect™	Dexrazoxane hydrochloride, per 250 mg	Brand discontinued; generic alternatives are still active
J1443	Triferic®	Ferric pyrophosphate citrate solution, 0.1 mg of iron	Discontinued
J1444	Triferic® (for use in dialysate)	Ferric pyrophosphate citrate powder, 0.1 mg of iron	Discontinued
J1445	Triferic® Avnu	Ferric pyrophosphate citrate solution 0.1 mg of iron	Discontinued
J3310	Trilafon®	Perphenazine injection	Discontinued
J3320	Trobicin™	Spectinomycin dihydrochloride injection	Discontinued
J0200	Trovan®	Alatrofloxacin mesylate	Discontinued
J0697	Zinacef®	Cefuroxime injection	Brand discontinued; generic alternatives are still active
J9282	Zusduri™	Mitomycin, intravesical instillation, 1 mg	Replaces J9999

New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk

The following medications have been approved as additions to the crosswalk reference table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Boncresta™	Denosumab-mobz biosimilar to Prolia®	Therapeutic injection	
J3590	Enoby™	Denosumab-qbde 60 mg/mL injection biosimilar to Prolia	Therapeutic injection	
J3590	Jubereq®	Denosumab-desu biosimilar to Xgeva®	Therapeutic injection	Chemotherapy adjunctive ¹
J3590	Nufymco®	Ranibizumab-leyk biosimilar to Lucentis®	Therapeutic injection	

New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Oziltus™	Denosumab-mobz biosimilar to Xgeva	Therapeutic injection	Chemotherapy adjunctive ¹
J3590	Osvyrti®	Denosumab-desu biosimilar to Prolia	Therapeutic injection	
Q5136	Wyost®	Denosumab-bbdz injection, for subcutaneous use biosimilar to Xgeva	Therapeutic injection	Chemotherapy adjunctive ¹
J3590	Xtrebo™	Denosumab-qbde 120 mg/1.7 mL biosimilar to Xgeva	Therapeutic injection	Chemotherapy adjunctive ¹

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9184	Avgemsi™	Injection, gemcitabine hydrochloride (Avyxa), 200 mg	Therapeutic injection	Chemotherapy ¹
C9308	Kyxata™	Injection, carboplatin (Avyxa), 1 mg	Therapeutic injection	Chemotherapy ¹
J0162	Epinephrine	Injection, epinephrine (Fresenius), not therapeutically equivalent to J0165, 0.1 mg	Therapeutic injection	
J1308	Famotidine	Injection, famotidine, 0.25 mg	Therapeutic injection	
J0654	Liothronine	Injection, liothyronine, 1 mcg	Therapeutic injection	
J1736	Qamzova™	Injection, meloxicam (Delova), 1 mg	Therapeutic injection	
J1737	Xifyrm™	Injection, meloxicam (Azurity), 1 mg	Therapeutic injection	
J2250	Midazolam	Midazolam solution auto-injector 10 mg/0.7 mL	Therapeutic injection	
J2711	Prevduo	Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg	Therapeutic injection	
J3291	Tranexamic acid	Injection, tranexamic acid in sodium chloride, 5 mg	Therapeutic injection	
J3379	Valporate	Injection, valproate sodium, 5 mg	Therapeutic injection	
J3376	Vancomycin	Injection, vancomycin hydrochloride (Hikma) not therapeutically equivalent to J3373, 10 mg	Therapeutic injection	Home health/infusion ²
J2596	Vasopressin	Injection, vasopressin (long grove), not therapeutically equivalent to J2598, 1 unit	Therapeutic injection	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/alpha-numeric.